The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST.
G. D. Demetri
Consultant or Advisory Role - GlaxoSmithKline; Infinity; Kolltan Pharmaceuticals; Novartis; Pfizer; Roche/Genentech
Stock Ownership - Kolltan Pharmaceuticals
Research Funding - Synta
M. C. Heinrich
Research Funding - Synta
B. Chmielowski
No relevant relationships to disclose
J. A. Morgan
No relevant relationships to disclose
S. George
No relevant relationships to disclose
R. Bradley
Employment or Leadership Position - Synta
Stock Ownership - Synta
R. K. Blackman
Employment or Leadership Position - Synta
Stock Ownership - Synta
F. Teofilovici
Employment or Leadership Position - Synta
Stock Ownership - Synta
J. A. Fletcher
Research Funding - Synta
W. D. Tap
No relevant relationships to disclose
M. von Mehren
Research Funding - Synta